Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

108.66 -2.20 (-1.98%)
Streaming Delayed Price Updated: 3:53 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies. 
Via The Motley Fool
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and... 
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Stocks That Could Double Your Money in 5 Years
These market-beating stocks could be just getting started. 
Via The Motley Fool
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.